TG therapeutics announces publication of clinical data from a Phase 1/2 trial of TG-1101 in the British Journal of Haematology

Company announced the publication of clinical data from a Phase 1/2 trial of TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkins Lymphoma (NHL) or Chrionic Lymphocytic Leukemia (CLL) previously exposed to rituximab. The data demonstrates single agent TG-1101 to be well tolerated with the most common adverse event observed […]